Hairy Cell Leukemia
📧 Sign up to get email alerts when something new happens for Hairy Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
NCI-sponsored clinical trial update describes collecting human samples to study hairy cell leukemia and other leukemias, and to develop reco…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia [Phase 2]
A Phase 2 trial sponsored by Scripps Health evaluated low-dose vemurafenib with rituximab for hairy cell leukemia. The study status is compl…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) [Phase 2]
A Phase 2 clinical trial evaluating the combination of vemurafenib and obinutuzumab versus cladribine and rituximab in hairy cell leukemia, …
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating the combination of tovorafenib with rituximab in patients with hairy cell …
-
CLINICAL_TRIALS other · 2026-04-14Clinical Trial Update: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia [Phase 2]
A Phase 2 clinical trial evaluating venetoclax for relapsed hairy cell leukemia is currently recruiting, sponsored by the National Cancer In…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia [Phase 2]
This update describes an ongoing Phase 2 trial of ibrutinib for relapsed hairy cell leukemia and hairy cell leukemia variant. The study is c…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant [Phase 1]
Phase I clinical trial evaluating anti-CD22 CAR-T cells in patients with relapsed/refractory hairy cell leukemia and hairy cell leukemia var…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant [Phase 2]
This clinical trial update notes a Phase 2 study evaluating binimetinib for relapsed/refractory BRAF wild-type hairy cell leukemia and its v…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL [Phase 2]
This clinical trial update reports a Phase 2 study of encorafenib plus binimetinib for BRAF V600-mutated hairy cell leukemia, which is curre…
-
FDA approval · 2026-03-27FDA Approved: CLADRIBINE — Original Application (Sandoz Inc.)
FDA approved Sandoz's generic version of cladribine under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies [Phase 2]
Phase 2 trial of Brexucabtagene Autoleucel in adults with rare B-cell malignancies has been terminated with results posted.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia [Phase 2]
A Phase II trial is evaluating the combination of vemurafenib and obinutuzumab in patients with previously untreated classical hairy cell le…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies [Phase 1]
A Phase 1 trial evaluating flotetuzumab for relapsed or refractory CD123-positive hematologic malignancies has completed, providing initial …
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia [Phase 2]
A Phase 2 clinical trial update describes evaluating the combination of cladribine and rituximab for hairy cell leukemia, currently recruiti…
-
CLINICAL_TRIALS other · 2025-12-08Clinical Trial Update: Registry of the German CLL Study Group
Ongoing registry study by the German CLL Study Group recruiting participants for trials involving chronic lymphocytic leukemia, small lympho…
-
FDA approval · 2025-11-24FDA Approved: CLADRIBINE — Original Application (Apotex Corp.)
FDA approves Apotex Corp.'s original ANDA for cladribine, a generic version of the cancer drug, intended for hairy cell leukemia.
-
FDA approval · 2025-11-03FDA Approved: NIPENT — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Nipent (pentostatin) submitted by Hospira, Inc.
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
Phase 2 trial results for the BRAF inhibitor vemurafenib in relapsed or refractory hairy cell leukemia have been completed and posted.
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia [Phase 2]
Phase 2 trial evaluating cladribine given with simultaneous or delayed rituximab for hairy cell leukemia; results have been posted as of 202…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
A US post-marketing safety trial for LUMOXITI in hairy cell leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: Hairy Cell Leukemia Patient Data Registry
A clinical trial update for a Hairy Cell Leukemia patient data registry sponsored by Ohio State University Comprehensive Cancer Center. The …